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Abstract
Objective/Background: Mixed chimerism is a major concern after allogenic hematopoietic stem cell transplantation
(HSCT) using a reduced-intensity conditioning (RIC) regimen in primary immunodeﬁciencies (PIDs). A donor
lymphocyte infusion (DLI) escalating dose regimen has been developed with the aim of reducing toxicity while preserving efﬁcacy. However, the graft-versus-host disease (GvHD) development remains the most common and adverse
effect of DLI and continues to be a limiting factor in its application, especially nonmalignant diseases such as PIDs. We
prospectively evaluated PID patients after HSCT using RIC in Children s Medical Center, who were candidates for an
escalating dose of DLI for MC from 2016 to 2018.
Methods: With the median follow-up of 16.4 months, 12 patients (nine males and three females) with a median age of
3.72 years received DLI. The median number of DLI was 3.2 (range, 1e5), the maximum and total dose of DLIs administered per patient were 3.6 £ 107 (range, 1e5) cells/kg CD3þ and 9.3 £ 107 (range, 1e15) cells/kg CD3þ cells, respectively.
Results: Median donor chimerism at baseline before the DLIs was 41% (range, 11e73%), patients received DLIs at a
median of 105 (range, 37e230) days and 52 (range, 3e168) days after the HSCT and onset of the MC, respectively. At the
ﬁnal assessment, six (54.5%) patients improved after DLIs at a median of 47.3 days.
Conclusion: PID patients may beneﬁt from DLI with an escalating dose regimen, but the GvHD development remains a
concern during the DLI, and the optimum dose and frequency must be standardized.
Keywords: Donor lymphocyte infusion, Hematopoietic stem cell transplantation, Mixed chimerism, Primary
immunodeﬁciency

1. Introduction

P

rimary immunodeﬁciencies (PIDs) are a heterogeneous group of inherited disorders
characterized by impairment of innate or adaptive
immunity, which results in high susceptibility to
infection and commonly leading to lethal complications [1]. Hematopoietic stem cell transplantation

(HSCT), despite improvements in supportive care
approaches, is currently the only curative procedure
for the majority of PIDs [2]. HSCT was restricted
initially to severe combined immunodeﬁciency
(SCID) patients [3]. Now there is an expanding list of
other PIDs such as chronic granulomatous disease
(CGD), leukocyte adhesion deﬁciency (LAD), major
histocompatibility complex class II deﬁciency
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(MHC-II def.), and defects in cytokine signaling
pathways [1].
Many PID children have signiﬁcant comorbidities
at the time of HSCT. The conventional myeloablative preparation may be associated with signiﬁcant treatment-related toxicity and also a long-term
consequence [4]. The use of reduced-intensity conditioning (RIC) enables HSCT in patients with preexisting comorbidities that have precluded it by
using conventional approaches. Using RIC for PIDs
is now the treatment of choice in many institutions,
especially in the presence of severe infections [5,6].
Mixed chimerism (MC) and graft loss occur in a
proportion of PID children who receive RIC
regimen for HSCT [7]. Moreover, MC, a common
condition following the RICeHSCT, has been under
survey for ambiguity surrounding its power to
resolve symptoms of the underlying disease [8].
While MC is likely to correct the phenotypic
expression of most PID children, the donor lymphocyte infusion (DLI) used to increase donor chimerism
or second HSCT procedures may be required [5,6].
The ﬁrst clinical trial that demonstrated DLI efﬁcacy
was reported in relapsing chronic myeloid leukemia
(CML) patients post-HSCT by Kolb et al. [9]. DLI then
has broadly been used after allogenic HSCT either to
enhance donor chimerism after non-myeloablative
conditioning/RIC or to treat disease relapse [10].
However, the time and dosage of DLI that can be
administered with relative safety, particularly in the
reduced-intensity setting, remain deﬁned; its early
administration, in combination with persistent host
antigen-presenting cells, has an impact on graftversus-host disease (GvHD) development, which remains the most common and adverse DLI effect
[11,12] as well as continuing to be a limiting factor in
its application, especially in nonmalignant diseases.
The escalating dose approach has been developed
with the aim of reducing toxicity while preserving
efﬁcacy, and relies on repeated donor T-cell infusions. It starts from a low T-cell dose and increases
at regular intervals, until the patient gets GvHD-free
and does not achieve the predeﬁned therapeutic
target [13,14]. In this study, we evaluate the efﬁcacy
of a graded dosing regimen of CD3þ cells in correcting MC, as well as minimizing the DLI-induced
GvHD risk in PID patients receiving HSCT after RIC.

2. Patients and methods

Medical Center from 2016 to 2018. The institutional
review board approved this study. A signed consent
was obtained from the children’s parents, who were
the treatment modality’s candidates.
2.2. Patient characteristics
Of total 46 PID patients who received HSCT, 12
(26%) were candidates for DLI from the original
stem cell donor: ﬁve patients with SCID, two with
LAD, two with CGD, two with MHC II def., and one
with WiskotteAldrich syndrome. The majority of
the patients were boys (75%), with a median age of
3.72 (range, 0.2e14) years.
2.3. Conditioning regimen protocol
All patients received an equal RIC regimen: a
combination of Fludarabine (Emcure e baxter;
Delhi, India) 30 mg/m2 intravenously (IV) for 5
consecutive days (Days 8 to 4), Melphalan
(Zytotoxisch, Germany) 70 mg/m2 IV for 2 consecutive days (Days 3 and 2), and rabbit antihuman
thymocyte immunoglobulin (Thymoglobulin 5 mg/
mL; Genzyme Polyclonal S.A.S, France) 2.5 mg/kg
for 4 consecutive days (Days 4 to 1).
2.4. GvHD prophylaxis regimen
GvHD prophylaxis at the initial HSCT time was
performed with Cyclosporin A (Novartis, US) 1.5
mg/kg daily IV starting on Day 1, then 3 mg/kg
from Day 7, plus Methylprednisolone (Pﬁzer
Oncology, US) 1 mg/kg/day IV starting on Day 5
(Day 5 to 7), then 0.5 mg/kg/day to Day þ14. The
CsA level was monitored twice weekly (therapeutic
range, 100e250 ng/mL).
2.5. Transplant characteristics
Patients received G-CSF (McMillan, UK)e
mobilized peripheral blood (PB) stem cells from an
HLA-matched sibling donor (MSD; n ¼ 4), HLAmatched other-related donor (MOD; n ¼ 7), and
single-locus mismatched unrelated donor (MMUD;
n ¼ 1) (Table 1).
Neutrophil and platelet (Plt) engraftments were
deﬁned when the absolute neutrophil and Plt count,
without Plt transfusion support, exceeded 500/mL
and 20  103/mL, respectively, on 3 consecutive days.

2.1. Study design and data collection
2.6. Donor chimerism measurement
This prospective study evaluates the result of
escalating doses of DLI as an intervention for MC in
PID patients treated with HSCT at Children‘s

Whole blood donor chimerism was generally
monitored routinely at Days þ15, þ30, þ60, þ90,
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Table 1. Donor/Recipient Characteristics and Transplant Details of Patients Undergoing Donor Lymphocyte Infusion for Mixed Donor Chimerism.
Patients#

1
2
3
4
5
6
7
8
9
10
11
12

Sex

M
M
M
M
M
M
F
M
F
F
M
M

Type of
disease

Time from diagnosis
to transplant s(months)

Age at
transplant (years)

Donor characteristics
Age (years)

Sex

Relationship/matching

LAD
CGD
CGD
SCID
WAS
SCID
LAD
SCID
MHC-II Def.
SCID
MHC-II Def.
SCID

18
8
21.5
10
3
1.5
6
2
6
4
2
4

4.5
2
5
1
1.3
0.2
14
0.3
12
0.5
14
0.8

17
35
7
27
8
38
21
9
30
21
10
25

M
M
F
F
M
F
M
F
F
M
F
F

MSD
MOD
MSD
MOD
MOD
MOD
MSD
MSD
MOD
MOD
MOD
MMUD

Note. CGD ¼ Chronic granulomatous disease, F ¼ female; LAD ¼ leukocyte adhesion deﬁciency; M ¼ male; MHC-II Def. ¼ major
histocompatibility complex II deﬁciency; MMUD ¼ single-locus mismatched unrelated donor; MOD ¼ HLA-matched other-related
donors; MSD ¼ HLA-matched sibling donors; PID ¼ primary immunodeﬁciency; SCID ¼ severe combined immunodeﬁciency; WAS ¼
WiskotteAldrich syndrome.

þ180, þ360, and þ2 years after HSCT but weekly after
the occurrence of MC. In patients with opposite-sex
donors, chimerism was monitored by ﬂuorescent in
situ hybridization with X and Y chromosome probes.
In patients with same-sex donors, donor chimerism
was monitored with PCR ampliﬁcation for one highly
variable short tandem repeats, which was followed by
capillary electrophoresis for size discrimination, to
determine the various alleles at 16 individual loci as
well as speciﬁc X and Y chromosomes products. All
whole blood chimerism studies were performed in
the clinical genetics laboratory. The presence of <95%
of donor cells in the recipient’s bone marrow or PB
was deﬁned as MC [7].
2.7. DLI and treatment outcomes evaluation
Patients with PIDs were treated with the escalating DLI dose when their whole blood donor
chimerism, despite the immunosuppression’s
discontinuation, dropped to less than 75%. PB
lymphocytes were collected by an Optia continuous
apheresis device using CMNC program from the
same donor used for the initial transplant and
infused into the recipient without any conditioning.
The collected cells were aliquot and cryopreserved,
except the ﬁrst dose, which was given freshly to the
patient on the same collection day. The escalating
CD3þ cell dose was used starting from 1e2  107
cells/kg, depending on the physician’s decision. The
additional DLI was administered at 3 or 4 weeks of
intervals in increasing doses (1  107 cells/kg per
dose) until either GvHD or a stabilization/reversal
of MC was observed, without exceeding ﬁve DLI in
total. The response to DLI was deﬁned as the donor
chimerism increase of at least 20% after DLI. Complete response to DLI was deﬁned as the donor

chimerism of 95%. Otherwise, a <20% increase or
any decline in donor chimerism was considered as
no DLI response. Stabilized chimerism was deﬁned
if the donor chimerism increased < 20% but not
declined after DLI [7,15]. Acute and chronic GvHD
(aGvHD and cGvHD) were diagnosed and graded
using standard criteria [16,17].
2.8. Statistical analysis, data collection, and
statistical methods
Data were analyzed using the Statistica 9.0 software package (StatSoft, Tulsa, OK, USA). Results are
presented as medians with ranges for quantitative
variables, number and percentage for qualitative
variables, and p values where appropriate. Signiﬁcance was set at p  0.05. Variables examined were:
underlying diseases, age at HSCT, time from diagnosis to HSCT, donor characteristics (age, relation,
HLA matching, ABO blood groups, and sex), age at
ﬁrst DLI, chimerism at Day þ15, time for ﬁrst loss of
donor chimerism after HSCT, the time between MC
and ﬁrst DLI, the time between ﬁrst DLI and HSCT,
MC baseline before ﬁrst DLI, peak chimerism after
DLI, number of DLIs, the ﬁrst dose, maximum dose,
total CD3þ T-cell dose (107 cell/kg), GvHD, and
infection after DLI.

3. Results
3.1. Patients, donors, and engraftment
characteristics
A total of 46 PID patients received HSCT, 12
children were managed with DLI for MC after PB
HSCT, the median age of donors was 21 (range,
7e38) years, the median number of infused white
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blood cells, mononuclear cells, CD34þ cells, and
CD3þ cells was 9.9  108 cells/kg, 8  108 cells/kg,
6.2  106 cells/kg, and 337  106 cells/kg, respectively. Engraftment occurred in all patients; the
median times to neutrophils and Plt engraftments
were 12 (range, 10e14) days and 16 (range, 15e18)
days, respectively.
Full and mixed (a median of 37% [range, 17e49%])
donor chimerisms were seen in eight (66.6%) patients and four (33.3%) patients on Day 15 posttransplant, respectively.

details regarding chimerism and DLI response is
displayed in Table 2. Median donor chimerism at
baseline before the DLIs was 41% (range, 11e73%);
patients received DLIs at a median of 105 (range,
37e230) days and 52 (range, 3e168) days after the
HSCT and after the onset of the MC, respectively. At
the last assessment, six (54.5%) patients showed
improvement after DLIs at a median of 47.3 (range,
23e110) days. In four (36.4%) patients, complete
donor chimerism was achieved, while the DLI
response was stabilized in two (18.2%) patients, with
a median of 44% (range, 35e53%). By contrast, ﬁve
(45.4%) patients had no improvement in donor
chimerism after DLIs and continued with mixed
donor chimerism at a median of 29% (range,
10e42%).

3.2. General characteristics of DLIs
The ﬁrst DLI infusion dose was 1  107 CD3þ
cells/kg in seven (58.3%) patients, while ﬁve (41.7%)
patients received 2  107 CD3þ cells/kg. The median
number of DLI was 3.2 (range, 1e5), the maximum
and the total dose of DLIs administered per patient
was 3.6  107 (range, 1e5) cells/kg and 9.3  107
(range, 1e15) cells/kg, respectively. In total, out of 12
patients, four (33.3%) received four DLIs, and the
rest, every two (16.67%) patients received 1, 2, 3, and
5 DLIs, respectively.

3.4. Factors affecting the response to DLI
We classiﬁed patients as the DLI responders (at
least 20% MC improvement after DLI) and non-responders (MC non-increase or continuous decrease)
to analyze the factors affecting the DLI response. No
signiﬁcant role of the examined variables, except the
donor chimerism level at Day þ 15 post-HSCT and
aGvHD ( p values: 0.0283 and 0.0084, respectively),
were found in the DLI response. Although the time
interval between transplant and initial MC was
lower in the responder group, it was not signiﬁcant
between the two groups. Table 3 illustrates the

3.3. Chimerism response after DLI
Donor chimerism improvement after DLIs was
analyzed in 11 patients because one of the patient
died before assessing the level of chimerism. The
Table 2. Donor Chimerism and Overall Response after DLI.
Patients #

Chimerism
in Day þ 15

Chimerism
before ﬁrst DLI

Chimerism in
last follow-up

Number
of DLIs

Time between
HSCT and ﬁrst DLI

Days from
DLI to aGVHD

Follow-up
time (months)

1
2
3
4
5
6
7
8
9
10
11

95
34
49
98
95
99
100
17
99
100
48

31
34
11
58
48
73
47
23
37
68
22

10
99
99
35
49
20
99
53
18
42
35

4
1
2
4
5
4
2
3
5
3
4

210
52
106
230
104
90
131
37
57
92
42

d
12
105
d
d
d
66
60
d
d
84

23
26
24
24
15
15
8
8
8
15
14

Note. aGvHD ¼ Acute graft-versus-host disease; DLI ¼ donor lymphocyte infusion; HSCT ¼ hematopoietic stem cell transplantation.
Table 3. T-Cell DLI for Mixed Donor Chimerism: Characteristics for Responders Compared to Non-Responders.
Donor chimerism at Day þ 15
Mean ﬁrst CD3þ cell dose (£107 cells/kg)
Day post-transplant for ﬁrst DLI
Day post-transplant for initial mixed chimerism
Day between chimerism drop and ﬁrst DLI
Last chimerism before starting DLI (%)
aGvHD following DLI

All patients (n ¼ 11)

Responders (n ¼ 6)

Non-responders (n ¼ 5)

p

76
1.5
104.6
49.7
52.1
41
5

57.8
1.3
76.3
37.5
38.7
34.955
5

97.4
1.6
138.6
64.4
68.2
48.4
0

0.028
0.42
0.10
0.07
0.32
0.33
0.008

Note. aGvHD ¼ Acute graft-versus-host disease; DLI ¼ donor lymphocyte infusion. The signiﬁcance of data is shown in Bold font.
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characteristics of DLI responders compared with
non-responders. Although not reaching the signiﬁcance level, 75% of patients who received HSCT
from MSD were responders to the escalated DLI
dose versus 42.8% of MOD recipients.

post-transplant for the ﬁrst DLI were different, but
did not reach a signiﬁcance level. After DLI, cytomegalovirus reactivation occurred in three patients
(27.3%) that showed an appropriate response to
treatment by ganciclovir.

3.5. DLI-associated complications

3.6. Treatment outcome

3.5.1. GvHD after DLI
Five (45.5%) patients developed Grade IIeIV
aGvHD after DLIs. Involvement of the skin (n ¼
2), liver (n ¼ 2), and both organs (n ¼ 1) was found in
patients with GvHD. The maximum aGvHD rate in
children with CGD, SCID, LAD, and MHC II deﬁciency was 100%, 40%, and 50% of each, respectively. The aGvHD grade II-IV was observed after
HSCT and the ﬁrst DLIs on median 122 (range,
42e211) days and 65 (range, 12e105) days, respectively. All patients who developed aGvHD were
responders, of which three achieved full donor
chimerism (FDC). The MOD and MSD HSCTs were
used in two (40%) patients and three (60%) patients,
respectively. The aGvHD resolved in all affected
patients after DLI was stopped and the use of 1 mg/
kg prednisolone.
Limited cGvHD was noted in one (8.3%) patient
with SCID, receiving MOD transplants, with a history of aGvHD after HSCT.

Among 12 patients who received DLIs, 11 (91.6%)
patients were alive at a median of 16.4 (range, 8e26)
months after DLI. The cause of death was disseminated invasive Bacillus CalmetteeGu
erin (BCGosis)
in one (8.3%) patient with SCID who received HSCT
from MMUD. Two patients had MC of less than
20%, but still more than 10%. All 11 patients are
healthy and without any sign of PIDs.

3.5.2. Risk factors for aGvHD after DLI
We analyzed the results of this study comparing
patients who developed aGvHD with those without
aGvHD after DLI in PID patients to identify the
factors affecting GvHD (Table 4). The chimerism
level on Day þ15, the last chimerism before starting
DLI, and the DLI response had a signiﬁcance level.
The patient’s age at DLI and the number of days of

4. Discussion
Because of increased reduced-intensity preparative regimens use for non-malignant diseases,
mixed donor chimerism is increasingly common in
the pediatric HSCT setting [15]. DLI is useful for MC
treatment potentially. However, the conventional
approach is usually associated with GvHD, which
can be severe in many cases. The escalating dose
approach has been developed with the aim of
reducing toxicity while preserving efﬁcacy [14,15].
Our results showed the efﬁcacy of escalated DLI
doses in correcting MC in six (54.5%) PID pediatric
patients post-HSCT using the RIC regimen, of
which four (˃95%) patients achieved FDC, while ﬁve
(45.5%) did not respond to DLI. It is necessary to
note that these results were similar to those of other
studies with DLI conventional usage. Haines et al.
[15] reported regarding DLI treatment outcomes in
MC after a similar RIC regimen in children with

Table 4. T-Cell DLI for Mixed Donor Chimerism: Risk Factors for aGvHD after DLI.

Donor type
MSD
MOD
Sex mismatching
Blood group mismatch (ABO)
CMV infections after DLI
Response to DLI
Patient age at time of DLI (months)
Donor chimerism at Day þ 15
Day post-transplant for ﬁrst DLI
Day post-transplant for initial mixed chimerism
Day between chimerism drop and ﬁrst DLI
Last chimerism before starting DLI (%)

With aGvHD(n ¼ 5)

Without aGvHD(n ¼ 6)

p

3 (60%)
2 (28.5%)
4 (80%)
2 (40%)
1 (20%)
5 (100%)
85 ± 79
50 ± 31
74 ± 42
39 ± 32
39 ± 32
27 ± 14

1 (16.6%)
5 (71.5%)
4 (66.6%)
3 (50%)
2 (66.7%)
1 (16.6%)
17 ± 19
97 ± 2
131 ± 71
63 ± 53
62.7 ± 53.3
52 ± 17

0.1553
0.1754
0.6385
0.7518
0.6374
0.0084
0.0696
0.004
0.1503
0.4080
0.2484
0.0277

Note. aGvHD ¼ Acute Graft-versus-host disease; CMV ¼ cytomegalovirus; DLI ¼ donor lymphocyte infusion; HSCT ¼ hematopoietic
stem cell transplantation; MOD ¼ HLA-matched other-related donors; MSD ¼ HLA-matched sibling donors. The signiﬁcance of data is
shown in Bold font.
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nonmalignant diseases and indicated that donor
chimerism increased by >20% in 56% of patients; of
these, with 37% achieved FDC, while 44% had no
signiﬁcant chimerism improvement after DLI. In
another study, Umeda et al. [18] demonstrated that
50% of pediatric patients with nonmalignant diseases (PID, inherited metabolic disease, bone
marrow failure syndrome, or histiocytosis) with MC
converted to complete chimerism after DLI. In
contrast, based on our previous experience, 80% of
pediatric nonmalignant disorders achieved sustained mixed or converted to FDC [19]. This difference in success rate may be due to the type of
underlying diseases and conditioning regimen.
Also, these results are with the concordance of
many studies comparing the efﬁcacy of escalating
DLI with the conventional DLI, which reported that
both groups had the same probability of achieving
the therapeutic target [14]. Regarding the DLIinduced GvHD risk, in the conventional approach,
approximately 40e60% of patients who received DLI
developed GvHD [10,20,21]. By contrast, GvHD was
much lower in CML patients receiving the escalating doses than in patients treated with a single
DLI infusion (10% vs. 44%, p ¼ .01), while 60% of
patients with non-Hodgkin lymphoma developed
GvHD after dose-escalated DLI with 14.7% aGvHD
[22].
Fozza et al. [23] reported that 15% of CML patients
had Grade IIeIV aGvHD after DLI with an escalating dose regimen. Although cell dose did not
correlate with aGvHD development, the interval
from HSCT to last DLI and male recipients of female
donor cells have demonstrated a positive correlation
with aGvHD incidence. By contrast, in our study,
45.5% of PID patients developed aGvHD. Risk factors of aGvHD were the level of chimerism at Day
þ15 because of the better DLI response of the patients with lower donor chimerism, which may be
related to earlier initiation of this treatment modality in this situation.
The DLI number and mean total CD3þ dose are
signiﬁcantly lower in the responder group than in
the non-responder group. Therefore, it seems that
the most DLI response will occur after the initial
doses, and there is no signiﬁcant change in the
treatment response with the increasing frequency of
DLI.
It appears that patients who responded not only
had lower donor chimerism but also a faster drop
and received DLI sooner; however, it is difﬁcult to
make any interpretation from these data with only a
few patients. Also, none of the patients in our study
showed signs of PID regardless of DLI response
because the DLI stabilized the lymphocyte

chimerism and prevented rejection in the nonresponder group. We are not able to justify this
point because of our restrictions on the lymphocyte
chimerism analysis.

5. Conclusions
Despite the small number of patients, our study
results demonstrate that using DLI with an escalating dose regimen is successful in correcting or
stabilization MC in pediatric patients with PIDs. The
response rate peaks were seen after the initial doses.
The lower the chimerism level, the better the DLI
response, especially on Day þ15, so it is recommended to closely monitor the chimerism for several
months after RIC-based HSCT in PID patients.
However, the DLI optimum dose and frequency
must be standardized. A multicenter study with a
large sample size and analytical analysis needs to
deﬁne the safe donor T-cell dose and the optimal
administration time.
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